An anhydrous 10 mg/g (1.0% w/w) chlortetracycline hydrochloride ophthalmic ointment intended for infectious bovine keratoconjunctivitis is compounded as a sterile dispersion in a white petrolatum/mineral oil base rather than an aqueous gel. The anhydrous carrier is not a convenience; tetracyclines form 4-epichlortetracycline and anhydrochlortetracycline related substances when free water is available at pH above 6.5, and autoclaving at 121°C accelerates epimerization and dark discoloration. The base is heated to 70°C for sterilization and viscosity reduction, screened through a 75 µm filter, then cooled to 42–45°C before micronized API is incorporated through a triple-roller mill set to a 50 µm gap. Deaeration is then performed under vacuum of 0.08 MPa prior to filling into 3.5 g or 10 g aluminium/PE ophthalmic tubes. Release testing follows USP <71>, <51>, <61>, and <62>; the API monograph for chlortetracycline hydrochloride controls related substances and assay on the dried basis, including the 4-epimer and anhydro degradation products. Where US regulatory jurisdiction applies, 21 CFR 524.160 governs chlortetracycline ophthalmic and topical dosage forms. The terminal product is a sterile veterinary ophthalmic ointment sealed with tamper-evident tip and stored below 25°C; terminal steam sterilization after filling is not applied because thermal input above 55°C shifts the related-substance profile outside the compendial acceptance window.

What Limits CTC Hydrochloride Stability in Poultry Drinking Water Lines?

Drinking water soluble powders intended for broiler, layer, and turkey flocks are formulated with 200 g/kg CTC HCl on a lactose monohydrate carrier, with citric acid added to depress final water pH into 4.0–5.5 after reconstitution. This pH band is dictated by the amphoteric behaviour of chlortetracycline hydrochloride, with pKa values at approximately 3.3, 7.4, and 9.3; the zwitterionic form between pH 5.0 and 7.0 has limited water solubility, while pH above 8.0 accelerates oxidative degradation and epimer formation. A farm stock solution is prepared at 100 g/L and proportioned through a medicator at 1:1000 to deliver 10–20 mg/kg body weight per day for 5 days, depending on the licensed indication and actual water intake. During manufacturing, the API is pre-sieved through a 60 mesh screen and blended for 20 minutes in a twin-shell blender at ambient RH <40%; the powder is then packed into PET/Al/LDPE sachets of 100 g, 500 g, and 1 kg to exclude moisture and photodegradation. Release testing includes loss on drying and related substances according to the current USP/Ph. Eur. Chlortetracycline Hydrochloride monograph, and residue compliance in poultry muscle is set at 100 µg/kg under EU Commission Regulation (EU) No 37/2010. The terminal product is a water-soluble powder for oral administration through drinking water lines. The primary field failure observed with this format is not incomplete dissolution but hanging droplet filters clogged by hard water cations; therefore, the formulation is not recommended for water sources above pH 8.0 without acidification.

Swine Enteritis Premix Manufacture and Chelation-Driven Carrier Constraints

In medicated feed premixes for growing swine, the API is commonly supplied as a 100 g/kg or 200 g/kg CTC HCl premix on a non-calcareous carrier such as rice hulls, ground corn cobs, or soybean mill run. Free calcium and magnesium from limestone carriers are excluded because tetracyclines chelate divalent cations, and the resulting complexes reduce intestinal absorption while interfering with assay recovery during feed mill quality control. The licensed finished feed concentration is calculated from the target daily dose; under 21 CFR 558.128, CTC use in swine for bacterial enteritis is anchored to 10 mg/lb body weight per day, which corresponds to finished feed concentrations of 440–550 g/tonne when daily intake is 4–5% of body weight. In the feed mill, the 200 g/kg premix is charged through a micro-ingredient bin and metered at 0.25–0.5% w/w into a horizontal ribbon mixer with a 6-minute dry cycle, followed by the addition of ground corn and soy meal. Carryover prevention requires flushing with ground corn after the batch, and assay samples are taken at the mixer discharge to verify homogeneity across 10 sample points. The finished medicated feed is bagged into 25 kg or 50 kg paper-lined woven polypropylene bags or loaded into bulk feed bins, with label instructions stating withdrawal period and VFD status. Oversight is split between 21 CFR 558.128 for the approved use and 21 CFR 225/226 for medicated feed manufacturing; the API must meet the current USP/Ph. Eur. Chlortetracycline Hydrochloride monograph before premix manufacture. The terminal product is an intermediate premix or complete medicated feed, depending on concentration and regional classification.

Dry granulation followed by compression is the preferred route for chlortetracycline hydrochloride tablets intended for preruminant calves and small-animal oral therapy, because aqueous wet granulation exposes the API to free water and elevated drying temperatures that accelerate 4-epimer formation. A 100 mg tablet formulation typically contains 50–60% w/w lactose monohydrate or mannitol as diluent, 5–8% w/w crospovidone as disintegrant, 1–2% w/w magnesium stearate as lubricant, and API equivalent to 100 mg chlortetracycline per unit. The blend is compacted by roller compaction at 12–18 kN and milled to obtain granules with a bulk density of 0.45–0.60 g/cm³ before final compression at hardness values of 50–80 N. Dissolution testing in 0.1 N HCl is conducted according to USP <711>, and single-dose content uniformity is evaluated under USP <905>; finished tablets are coated with a light-protective film because CTC HCl photodegrades to dark-coloured related substances. Capsule filling of 50 mg, 100 mg, and 250 mg formulations follows the same dry granulation pathway, with final product filled into size 3, 2, or 0 hard gelatin or HPMC capsules at a fill weight established by assay. The terminal product is an oral tablet or capsule for veterinary prescription use, packaged in amber HDPE bottles with desiccant, stored below 25°C and protected from light. The main processing boundary is compression dwell time: extended dwell above 55°C at the tablet press can soften low-melting excipients and increase tablet capping, so press speed and tooling condition are controlled.

When CTC HCl Is Requested for Injectable Solutions: pH and Oxygen Exclusion Thresholds

Parenteral CTC development is constrained by a narrow operating window between solubilisation and degradation. CTC HCl is an amphoteric molecule; solubilisation in aqueous vehicles requires pH adjustment with sodium hydroxide to 8.0–9.0, but holding the solution in this alkaline state accelerates oxidation and epimerization even at 20°C. Published data for this specific configuration is limited, and any injectable formulation should be developed as a nonaqueous or mixed co-solvent system rather than a simple aqueous solution. Where development work has been performed, a working concentration of 50 mg/mL CTC HCl is selected because higher concentrations exceed the solubility of the free base at ambient temperature. The vehicle is pre-deoxygenated by nitrogen sparging, and the API is dissolved with continuous pH monitoring. The solution is passed through a 0.22 µm membrane filter and filled into amber Type I glass vials under a nitrogen overlay; terminal steam sterilisation at 121°C is not applied because it destroys the tetracycline nucleus. Release testing includes sterility per USP <71>, bacterial endotoxins per USP <85>, particulate matter per USP <788>, and a related-substance profile consistent with the API monograph. The terminal product is a prescription injectable solution in 20 mL, 50 mL, or 100 mL amber Type I glass vials, stored at 2–8°C where the developed product data supports refrigerated holding. The main operational boundary is that any hold time between pH adjustment and filtration should be kept below 4 hours at 20°C, and contact with stainless steel surfaces should be minimised unless the surface is passivated, because trace iron and copper ions catalyse tetracycline degradation.

In jurisdictions where CTC HCl is authorised for aquaculture medicated feed, post-extrusion vacuum coating replaces pre-extrusion mixing because the 120–135°C barrel temperature of twin-screw extruders exceeds the degradation threshold of the tetracycline ring. The coating emulsion is prepared at 100 g/L CTC HCl in fish oil or soybean oil, and applied at 2–5% v/w to achieve 1–3 g active per kg finished pellet. Vacuum coating is carried out in a double-shaft paddle coater at a vacuum of 0.06–0.08 MPa and a product temperature of 40–55°C, followed by a 15-minute release cycle to allow oil absorption into the pellet pores. This process yields 2 mm and 4 mm sinking pellets with oil-stabilised surfaces that reduce dust and API loss during transfer; the finished product is packed in 20 kg or 25 kg woven polyethylene bags with an inner liner, labelled with the appropriate withdrawal period. Residue compliance is evaluated against EU Commission Regulation (EU) No 37/2010 muscle MRL of 100 µg/kg where applicable to traded product, and the API must meet the current USP/Ph. Eur. Chlortetracycline Hydrochloride monograph. The terminal product is a medicated aquaculture pellet, and the main processing limitation is that coating oil temperature must not exceed 60°C, because oxidative rancidity and CTC isomerisation both increase when hot oil is recirculated through the coater for extended periods.